Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.

@article{Mulders2012CediranibMI,
  title={Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.},
  author={Peter F A Mulders and Robert Hawkins and Paul N Nathan and Igle Jan de Jong and Susanne Osanto and Emilio Porfiri and Andrew Protheroe and Carla M L van Herpen and Bijoyesh Mookerjee and Laura Pike and Juliane M. J{\"u}rgensmeier and Martin Eric Gore},
  journal={European journal of cancer},
  year={2012},
  volume={48 4},
  pages={527-37}
}
BACKGROUND Cediranib is a highly potent vascular endothelial growth factor (VEGF) signalling inhibitor with activity against VEGF receptors 1, 2 and 3. This Phase II, randomised, double-blind, parallel-group study compared the efficacy of cediranib with placebo in patients with metastatic or recurrent clear cell renal cell carcinoma who had not previously… CONTINUE READING